Open Access. Powered by Scholars. Published by Universities.®

Life Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Pharmacology, Toxicology and Environmental Health

External Link

Selected Works

2011

Drug Design

Articles 1 - 4 of 4

Full-Text Articles in Life Sciences

Additivity In The Analysis And Design Of Hiv Protease Inhibitors, Robert Jorissen, G. S. Kiran Kumar Reddy, Akbar Ali, Michael Altman, Sripriya Chellappan, Saima Anjum, Bruce Tidor, Celia Schiffer, Tariq Rana, Michael Gilson Nov 2011

Additivity In The Analysis And Design Of Hiv Protease Inhibitors, Robert Jorissen, G. S. Kiran Kumar Reddy, Akbar Ali, Michael Altman, Sripriya Chellappan, Saima Anjum, Bruce Tidor, Celia Schiffer, Tariq Rana, Michael Gilson

Celia A. Schiffer

We explore the applicability of an additive treatment of substituent effects to the analysis and design of HIV protease inhibitors. Affinity data for a set of inhibitors with a common chemical framework were analyzed to provide estimates of the free energy contribution of each chemical substituent. These estimates were then used to design new inhibitors whose high affinities were confirmed by synthesis and experimental testing. Derivations of additive models by least-squares and ridge-regression methods were found to yield statistically similar results. The additivity approach was also compared with standard molecular descriptor-based QSAR; the latter was not found to provide superior …


Design Of Mutation-Resistant Hiv Protease Inhibitors With The Substrate Envelope Hypothesis, Sripriya Chellappan, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Visvaldas Kairys, Miguel Fernandes, Michael Altman, Bruce Tidor, Tariq Rana, Celia Schiffer, Michael Gilson Nov 2011

Design Of Mutation-Resistant Hiv Protease Inhibitors With The Substrate Envelope Hypothesis, Sripriya Chellappan, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Visvaldas Kairys, Miguel Fernandes, Michael Altman, Bruce Tidor, Tariq Rana, Celia Schiffer, Michael Gilson

Celia A. Schiffer

There is a clinical need for HIV protease inhibitors that can evade resistance mutations. One possible approach to designing such inhibitors relies upon the crystallographic observation that the substrates of HIV protease occupy a rather constant region within the binding site. In particular, it has been hypothesized that inhibitors which lie within this region will tend to resist clinically relevant mutations. The present study offers the first prospective evaluation of this hypothesis, via computational design of inhibitors predicted to conform to the substrate envelope, followed by synthesis and evaluation against wild-type and mutant proteases, as well as structural studies of …


Design And Synthesis Of Hiv-1 Protease Inhibitors Incorporating Oxazolidinones As P2/P2' Ligands In Pseudosymmetric Dipeptide Isosteres, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Robin Nathans, Celia Schiffer, Tariq Rana Nov 2011

Design And Synthesis Of Hiv-1 Protease Inhibitors Incorporating Oxazolidinones As P2/P2' Ligands In Pseudosymmetric Dipeptide Isosteres, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Robin Nathans, Celia Schiffer, Tariq Rana

Celia A. Schiffer

A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have been synthesized and evaluated. The inhibitors were designed by incorporating N-phenyloxazolidinone-5-carboxamides into the hydroxyethylene and (hydroxyethyl)hydrazine dipeptide isosteres as P2 and P2' ligands. Compounds with (S)-phenyloxazolidinones attached at a position proximal to the central hydroxyl group showed low nM inhibitory activities against wild-type HIV-1 protease. Selected compounds were further evaluated for their inhibitory activities against a panel of multidrug-resistant protease variants and for their antiviral potencies in MT-4 cells. The crystal structures of lopinavir (LPV) and two new inhibitors containing phenyloxazolidinone-based ligands in complex with wild-type …


Hiv-1 Protease Inhibitors From Inverse Design In The Substrate Envelope Exhibit Subnanomolar Binding To Drug-Resistant Variants, Michael Altman, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Sripriya Chellappan, Visvaldas Kairys, Miguel Fernandes, Michael Gilson, Celia Schiffer, Tariq Rana, Bruce Tidor Nov 2011

Hiv-1 Protease Inhibitors From Inverse Design In The Substrate Envelope Exhibit Subnanomolar Binding To Drug-Resistant Variants, Michael Altman, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Sripriya Chellappan, Visvaldas Kairys, Miguel Fernandes, Michael Gilson, Celia Schiffer, Tariq Rana, Bruce Tidor

Celia A. Schiffer

The acquisition of drug-resistant mutations by infectious pathogens remains a pressing health concern, and the development of strategies to combat this threat is a priority. Here we have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to stay within a consensus substrate volume in the binding site. Two rounds of design, synthesis, experimental testing, and structural analysis were carried out, resulting in a total of 51 compounds. Improvements in design methodology led to a roughly 1000-fold affinity enhancement to a wild-type protease for the …